Imagion Biosystems Ltd (ASX: IBX) Share Price and News

Ms Leydin is a prominent provider of specialized consulting and administrative services to clients in the Fund, Corporate, Capital Markets, and Private Wealth sectors. Ms Leydin has over 25 years of experience in the accounting profession and has experience holding Board positions including Company Secretary of ASX listed entities. She has experience in relation to public Company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganization of companies, initial public offerings, secondary raisings and shareholder relations.

Mr. Mitchell is a corporate finance executive with more than 15 years of experience in ASX listed companies leading transactions in the biopharmaceutical, mining, energy and tech industries. He has been involved in the founding, financing, and management of both private and publicly-listed companies, including recently as a director of ASX listed lithium developer Delta Lithium Ltd (DLI), the dual ASX-LSE listed medical cannabis Company Argent Biopharma Ltd (RGT), and is currently Executive Chairman of ASX listed Javelin Minerals Ltd (ASX:JAV) and Non-Executive Chairman of Uvre Limited . Additionally, Mr Mitchell has founded two financial advisory services businesses and brings a track record of capital raising and corporate strategy to Imagion.

Dr Webster brings to the Board an experience in the Australian ASX listed pharmaceutical industry, holding leadership roles over a thirty-year period. She currently serves as Managing Director and Chief Executive Officer of Dimerix Ltd (ASX: DXB), a clinical-stage biopharmaceutical company, developing a portfolio of drugs to treat inflammatory diseases. Formerly the Commercial Director for Acrux Limited (ASX: ACR) and Director of Commercialisation and Intellectual Property for Immuron Limited (ASX: IMC). Dr Webster currently also serves as Non-Executive Chairperson for SYNthesis BioVentures and as Non-Executive Director for Linear Clinical Research Limited.

Mr Proulx has served as Chairman of the Board at Imagion Biosystems since the Companys IPO in 2017. As President and CEO of Imagion Biosystems beginning in February 2015 until June 2023, he led the Company in the development of the nanoparticle-based medical imaging technology from early proof of concept through initial clinical development until June 2023.